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ORIGINAL ARTICLES

Effect of Obesity, Serum Lipoproteins, and Apolipoprotein
E Genotypes on Mortality in Hospitalized Elderly Patients
Filomena Addante,1 Daniele Sancarlo,1 Massimiliano Copetti,2 Carlo Scarcelli,1
Maria Grazia Longo,1 Valeria Niro,1 Giulia Paroni, 1 Fabio Pellegrini,2,3
Luigi Fontana,4 and Alberto Pilotto1

Abstract

Background: The aim of this study was to investigate the relationship among apolipoprotein E (APOE) polymorphism, body mass index (BMI), and dyslipidemia and how these factors modify overall mortality in a cohort
of hospitalized elderly patients.
Methods: Plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), BMI, and APOE genotype were evaluated in 1,012
hospitalized elderly patients, who were stratified into three groups according to their baseline BMI and APOE
allele status. Multivariate logistic regression analysis was used to assess whether APOE genotype, BMI, and
dyslipidemia are associated with mortality, adjusting for potential confounders. Interaction analysis was also
performed.
Results: Obese patients have significantly higher levels of TC and LDL-C compared to normal-weight and
overweight subjects, for both sexes. APOE e4 carriers have significantly higher levels of TC and LDL-C compared with e2 and e3 carrier both in males and females. Interaction analysis showed that women with
TC < 180 mg/dL, LDL-C < 100 mg/dL, normal weight, and e3 carrier (odds ratio [OR] ¼ 3.42, 95% confidence
interval [CI] 1.36–8.60) and men with LDL-C < 100 mg/dL, HDL-C < 40 mg/dL, and e3 carrier (OR ¼ 1.97, 95%
CI 1.04–3.74) were at highest risk of mortality.
Conclusions: In elderly hospitalized patients, obesity and APOE genotype influence the lipid profile and mortality risk. A significant interaction among BMI, dyslipidemia, and APOE genotype was observed that could
identify elderly patients with different risks of mortality.

Introduction

E

xcessive body weight is associated at all ages with
detrimental changes in the lipid profile. Higher body
mass index (BMI), a surrogate measurement of total body fat,
is associated with higher plasma concentrations of total
cholesterol (TC), low-density lipoprotein cholesterol (LDLC), and triglycerides (TG).1 Data from several epidemiological studies have also shown that apolipoprotein E (APOE)
polymorphism is associated with variation of serum TC and
LDL-C concentrations.2,3 APOE is a multifunctional glycoprotein that plays a key role in regulating lipoprotein metabolism and cardiovascular risk.4 The APOE gene exhibits a

genetic polymorphism with three common alleles ( e2, e3,
and e4), which encode for three protein isoforms E2, E3, and
E4.5 APOE polymorphism has been related to significant
modifications of the lipoprotein profile, with the e2 allele
being associated with lower and the e4 allele with higher TC
and LDL-C levels than the e3 allele.6,7 Isoform-specific effects
include the association of APOE e4 with increased risk for
atherosclerosis, stroke, impaired cognitive function, and
Alzheimer disease (AD).7,8–10 Moreover, some11,12 but not all,
population-based studies13,14 have found a negative or positive association between mortality risk and APOE e2 and
APOE e3 polymorphisms, respectively. However, to the best
of our knowledge, no study has investigated the interaction
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between APOE polymorphism, BMI, and dyslipidemia in a
large cohort of hospitalized elderly patients, in whom the
aging process and co-morbidity may have profound effects
on body composition and lipid metabolism.
The purpose of the present study was to evaluate the relationship among APOE polymorphism, adiposity, and
dyslipidemia in a large group of elderly patients who were
admitted to our hospital. A second aim was to study how
these factors affect prognosis by modifying overall mortality.
Methods
Study design
From January, 2006, to March, 2007, all patients consecutively admitted to the Geriatrics Unit of the ‘‘Casa Sollievo
della Sofferenza’’ Hospital, IRCCS, San Giovanni Rotondo,
Italy, were screened for inclusion in the study. Inclusion criteria were: (1) Caucasian race, (2) age 65 years; (3) ability to
provide an informed consent or availability of a proxy for
informed consent. Exclusion criteria were: (1) Diagnosis of
neoplasms; (2) medical/surgical hospitalization within 1
month before the study; (3) use of lipid-lowering drugs during
the previous 4 weeks. Patients with AD were included in the
study. Diagnoses of possible/probable AD were made according to the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association Work Group (NINDSADRDA).15 This study was approved by the Human Studies
Committee of ‘‘Casa Sollievo della Sofferenza’’ Hospital,
IRCCS, San Giovanni Rotondo, Italy, and all subjects gave
informed consent before their participation.
All measurements were performed during the hospital
admission examination. Height was measured without shoes
to the nearest 0.1 cm. Body weight was obtained on a balance
scale in the morning after subjects fasted for 12 h overnight.
BMI was calculated by dividing body weight (in kilograms)
by the square of height (in meters). According to the National Institutes of Health (NIH) guidelines, normal weight
was defined as a BMI 18.5 and 24.9 kg/m2, overweight
as a BMI  25 and 29.9 kg/m2, and obesity as a BMI
 30 kg/m2.16
Information on the vital status of the participants was
obtained at regular intervals from the municipal population
registries located in the towns where the patients resided at
the time of hospital admission. Mortality data were available
up to January 31, 2009.
Laboratory analysis
A venous blood sample was taken to determine lipid and
lipoprotein concentrations, and APOE genotypes after subjects had fasted for at least 12 h. Plasma levels of TC, TG,
LDL-C, and high-density lipoprotein cholesterol (HDL-C)
were measured by standardized enzymatic procedures and
expressed in mg/dL.
Genetic analysis
Genomic DNA was purified manually from peripheral
blood by organic protein extraction and ethanol precipitation
according to a standard method. The APOE genotypes were
determined by polymerase chain reaction (PCR) and agarose
gel electrophoresis as described previously.17 Briefly, a
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combination of four specific primers in three different pairs
sharing the same stringent PCR conditions was used. Allelespecific primers were: ASP1, CGG ACA TGG AGG ACG
TGT; ASP2, CGG ACA TGG AGG ACG TGC; ASP3, CTG
GTA CAC TGC CAG GCG; and ASP4, CTG GTA CAC TGC
CAG GCA, synthesized by Invitrogen (Invitrogen Corporation, Carlsbad, CA). The primer pair ASP-1/ASP-4 identifies
the e2 allele, the primer pair ASP-1/ASP-3 identifies the e3
allele, and the primer pair ASP-2/ASP-3 identifies the e4
allele. On an Applied Biosystems GeneAmp PCR System
9700, the amplification conditions were 948C for 2 min, followed by 32 cycles at 968C for 15 sec, 618C for 30 sec, and
728C for 30 sec. Reaction buffer included 1.5 U of Taq DNA
polymerase (PlatinumTaq, Invitrogen, Carlsbad, CA), 10
pmoles of each primer, 100 picomoles (pM) nucleoside triphosphates (NTPs), and 1 mM MgCl2. The presence/absence
of specific allele PCR products detected by electrophoresis
analysis on a 2% agarose gel identified the six APOE genotypes. Patients were classified into the following three phenotype groups: APOE e2, e3, and e4 groups. The e3/ e3
genotype was the reference category; subjects with the e2/ e2
or e2/ e3 genotypes were considered e2þ carriers and subjects with e3/ e4 or e4/ e4 genotypes were considered e4þ
carriers. Subjects who were carriers of the e2/ e4 genotype
were excluded from the analysis.
Statistical analysis
Patients’ baseline characteristics were reported as
mean  standard deviation (SD) or frequencies and percentages for continuous and categorical variables, respectively.
Baseline comparison between men and women was made
using the chi-squared test for categorical variables and the
Mann–Whitney U-test for continuous variables. Baseline
differences according to BMI groups and APOE alleles
groups were assessed with the analysis of variance (ANOVA)
F-test or chi-squared test for continuous and categorical
variables, respectively. p values for trend were estimated
using the Mantel–Haenszel chi-squared test and ANOVA
F-test for trend, appropriately. Genotype distribution according to the Hardy–Weinberg equilibrium was analyzed
by the exact chi-squared test.
Multivariate logistic regression analysis was performed to
investigate, separately, the association between BMI, dyslipidemia, APOE polymorphism, and all-cause mortality. The
following cutoffs were used to dichotomize dyslipidemia
variables: 180 mg/dL for TC, 100 mg/dL for LDL-C, 150 mg/
dL for TG, 40 mg/dL for HDL-C in men, and 50 mg/dL for
HDL-C in women. Results were shown and odds ratio (OR)
along their 95% confidence interval (95% CI).
Furthermore, to evaluate interactions among covariates and
identify distinct and homogeneous subgroups of patients in
terms of mortality, the REPCAM method was used.18 This
tree-based method integrates the advantages of main-effects
logistic regression and tree-growing techniques. At each partitioning step, the method chooses the covariate and its best
binary split to maximize the difference in the outcome of interest. The algorithm stops when user-defined conditions
(stopping rules) are met. To obtain a more robust and stable
split, a permutation approach was adopted to choose the best
splitting variable. Global adjustment for age, diabetes, AD,
and cardiovascular diseases was accounted for.

EFFECT OF OBESITY AND APOE ON MORTALITY
All analyses were performed separately for males and
females. All analyses were performed using SAS release 9.1.
For the RECPAM analysis, we used an SAS macroroutine
written by F. Pellegrini. p values <0.05 were considered
significant.
Results
Study population
From January, 2006, to March, 2007, 1,129 patients were
admitted consecutively to the Geriatric Unit of ‘‘Casa Sollievo della Sofferenza’’ Hospital in San Giovanni Rotondo
(FG). Of the 1,129 patients assessed for eligibility, 72 patients
were excluded because they were younger than 65 years, and
28 refused to participate. Because only 7 patients had a BMI
value less than 18.5, they were excluded from the analysis.
Thus, 1,022 patients (494 men and 528 women) with a mean
age of 77.6  6.7 years (range 65–100 years), were eligible for
the present investigation. Table 1 reports the characteristics
of patients included in the study, divided according to gender. Female patients had significantly higher BMI mean
values, higher serum TC, LDL-C, and HDL-C concentrations,
and a higher prevalence of hypertension than male patients
( p ¼ 0.0001). Age, serum TG concentration, and the prevalence of diabetes mellitus and AD were not significantly
different between male and female patients. The distribution
of the different APOE polymorphisms among all subjects
was as follows: 11.5% for the e2/e3 genotype (n ¼ 118), 71.2%
for the e3/e3 genotype (n ¼ 728), 15.3% for the e3/e4 genotype (n ¼ 157), 0.88% for the e4/e4 genotype (n ¼ 9), and 0.9%
for the e2/e4 genotype (n ¼ 10). No e2/e2 APOE genotypes
were observed. Patients with the e2/e4 genotype (n ¼ 10)
were not considered in the analysis. The observed genotype
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frequency distributions did not show statistically significant
differences compared with those expected under Hardy–
Weinberg equilibrium ( p ¼ 0.106). Estimated allele frequencies were 0.062 for the e2 allele, 0.846 for the e3 allele, and
0.085 for the e4 allele. The distribution of the APOE genotype
frequencies was not significantly different between males
and females (Table 1).
Table 2 shows the mean levels of serum lipids in patients,
divided according to BMI and gender. The effect of BMI on
serum lipid concentrations was studied by using BMI classes
(normal weight, overweight, and obese). The mean value of
BMI in the general population is 27.5  5.1 kg/m2; 336
(33.2%) patients were normal weight, 399 (39.4%) were
overweight, and 277 (27.4) were obese according to their
baseline BMI. In both male and female patients, BMI was
significantly associated with serum concentrations of TC and
LDL-C, but not with HDL-C. BMI was significantly associated with serum concentration of TG only in males.
APOE polymorphism, plasma lipid, lipoprotein
concentrations, and BMI
The bioclinical characteristics according to APOE polymorphisms are summarized in Table 3. No difference in the
mean age of the patients across the APOE polymorphisms
was observed. In both male and female patients, the mean
concentrations of TC and LDL-C were APOE genotype dependent; APOE e4 carriers had significantly higher levels of
TC and LDL-C compared to e2 and e3 carriers. In contrast,
there were no significant differences among APOE genotypes in plasma concentrations of HDL-C and TG. The effect
of APOE alleles on BMI was studied by using BMI as a
continuous variable or by using BMI classes (normal weight,
overweight, and obese). In both male and female patients,

Table 1. Baseline Characteristics of Patients Divided According to Gender

Mean age (years, mean  SD)
BMIa (kg/m2, mean  SD)
Diabetes mellitusa
Hypertensiona
Ischemic cardiomiopathya
Alzheimer dementia
Total cholesterolb
LDL-Cb
HDL-Cb
Triglycerides (TG)b
Allele frequencies (%)
e3( %)
e4(%)
e2(%)
Genotype frequencies
e 3/e 3a
e 2/e 3a
e 4/e 3a
e 4/e 4a
e 2/e 4a
1 year mortalitya
a

Total (n ¼ 1022)

Men (n ¼ 494)

Women (n ¼ 528)

p

77.6  6.7
27.5  5.1
206 (20.1)
411 (40.2)
87 (8.5)
180 (17.8)
165.9  45.7
100.9  36.7
39.5  14.9
119.1  66.5

77.4  6.7
26.7  4.3
92 (18.6)
161 (32.6)
54 (10.9)
83 (17.0)
158.4  44.0
95.9  36.7
37.1  13.5
115.3  62.9

77.7  6.7
28.3  5.6
114 (21.6)
250 (47.3)
33 (6.2)
97 (18.5)
173.5  45.9
105.6  36.0
41.8  15.8
122.6  69.5

0.490
0.000
0.274
0.000
0.007
0.532
0.000
0.000
0.000
0.083

85.4
9.9
5.4

0.657
0.180
0.134

84.6
8.5
6.2
728
118
157
9
10
161

(71.2)
(11.5)
(15.3)
(0.88)
(0.9)
(15.9)

84.6
8.1
7.1
349
65
73
1
6
94

(70.6)
(13.1)
(14.8)
(0.2)
(1.2)
(19.3)

379
53
84
8
4
67

(71.7)
(10.0)
(15.9)
(1.5)
(0.7)
(12.8)

Data are N8 (%).
Data are mg/dL.
SD, Standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C high-density lipoprotein.
b

0.749
0.148
0.688
0.140
0.615
0.005
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Table 2. Lipid Levels in Patients Divided According to BMI Classes
Men (n ¼ 488)
Normal weight
(n ¼ 180)

TC
TG
HDL-C
LDL-C

152.1  42.4
101.2  47.7
38.2  14.7
91.1  35.9

Overweight
(n ¼ 208)
159.1  44.5
122.3  66.0
36.3  13.7
96.3  38.5

Women (n ¼ 524)
Obese
(n ¼ 100)

165.9  44.3
123.1  70.1
36.9  10.5
103.1  36.7

p
a

0.038
0.001b
0.392
0.033c

Normal weight
(n ¼ 156)

Overweight
(n ¼ 191)

Obese
(n ¼ 177)

p

164.3  43.8
115.7  73.4
43.2  17.4
96.8  35.8

179.9  46.0
117.6  60.1
41.1  13.5
111.2  35.6

174.3  47.3
131.8  69.1
41.6  16.9
107.6  34.8

0.007 a
0.054b
0.462
0.001c

Data are mean  standard deviation (SD), mg/dL.
a
Men: normal weight vs, obese, p ¼ 0.036; women: normal weight vs. overweight, p ¼ 0.005.
b
Men: normal weight vs. overweight, p ¼ 0.002; normal weight vs, obese, p ¼ 0.013.
c
Men: normal weight vs. obese, p ¼ 0.028; women: normal weight vs. overweight, p ¼ 0.001; normal weight vs. obese, p ¼ 0.020.
BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.

there was no significant difference among APOE genotypes
between normal-weight, overweight, and obese patients
(Table 3).
Mortality data
A total of 161 deaths (15.9%) occurred during the follow
up. Males had significantly higher mortality rates than females (19.3% vs. 12.8%, p ¼ 0.005). Female patients who died
had significantly lower mean BMI than female patients who
survived (BMI ¼ 26.8  5.2 vs. 28.5  5.7, p ¼ 0.018); this difference was not found in male patients (BMI ¼ 26.1  4.3 vs.
26.8  4.2, p ¼ 0.118). Mortality was significantly higher in
normal weight patients than obese patients both in males
(40.4% vs. 20.2%, p for trend ¼ 0.001) and female (41.8% vs.
25.4%; p for trend ¼ 0.001). Male patients who died had a
significantly lower level of LDL-C (85.8  38.5 vs. 98.2  35.9;
p ¼ 0.003) and HDL-C (34.5  15.4 vs. 37.7  12.9; p ¼ 0.041)
than patients who survived, whereas TC (151.1  47.0 vs.
159.5  43.1; p ¼ 0.095) and TG levels (118.4  67.4 vs.
113.8  60.2; p ¼ 0.540) did not differ significantly. In female
patients, levels of TC (147.6  47.7 vs. 177.16  44.7;
p ¼ 0.000), LDL-C (92.8  36.8 vs. 107.6  35.4; p ¼ 0.002), and

HDL-C (37.3  14.7 vs. 42.6  15.9; p ¼ 0.016) were significantly lower in patients who died compared to survivors.
The APOE e2 carriers had lower mortality compared with
APOE e3 and e4 carriers both in males (8.5% vs. 75.5% vs.
16%) and females (6% vs. 80.6% vs. 13.4%) (Table 4). No
significant differences in the prevalence of AD were observed between patients who died versus survivors.
Multivariate logistic regression analysis, adjusted for
several confounding factors, indicates that obesity
(OR ¼ 0.486, 95% CI 0.255–0.927, p ¼ 0.028), TC > 180 mg/dL
(OR ¼ 0.350, 95% CI 0.187–0.657, p ¼ 0.001), and LDLC > 100 mg/dL (OR ¼ 0.456, 95% CI 0.235–0.882; p ¼ 0.020)
are factors significantly associated with a lower risk of
mortality in female patients. These associations were not
observed in male patients. No significant association between APOE genotype, higher TG, lower HDL-C level, and
1-year mortality was observed (Table 5).
Interactions
To investigate the interaction between APOE genotype,
BMI, lipid levels, and mortality, a RECPAM analysis was
performed separately for males and females leading to the

Table 3. Serum Lipid Levels and BMI Distribution in Patients Divided According
to Their APOE Allele Status
Men

Age
TCa (mg/dL)
TGa (mg/dL)
HDL-Ca (mg/dL)
LDL-Ca (mg/dL)
BMIa (kg/m2)
Normalweightd
Overweightd
Obesed
a

Women

e2/ (n ¼ 65)

e3/e3 (n ¼ 349)

e4/ (n ¼ 74)

p

e2/ (n ¼ 53)

e3/e3 (n ¼ 379)

e4/ (n ¼ 92)

p

77.9  6.9
141.8  42.5
116.8  71.9
36.5  11.9
80.7  34.9
26.9  3.7
19 (29.2)
33(50.8)
13 (20.0)

77.2  6.6
159.4  42.2
115.9  57.6
36.6  13.4
97.7  36.2
26.8  4.3
129 (37.0)
146 (41.8)
74 (21.2)

78.3  6.6
164.9  50.1
106.8  69.8
39.8  15.0
100.8  38.0
26.1  4.3
32 (43.2)
29 (39.2)
13 (17.6)

0.360
0.004b
0.489
0.183
0.001c
0.419
0.088
0.178
0.698

77.2  6.5
164.8  51.4
116.5  57.1
40.8  15.2
90.8  33.9
28.9  5.6
15 (28.3)
17 (32.1)
21 (39.3)

77.9  6.7
172.1  45.1
118.9  63.1
42.4  14.5
106.9  34.7
28.3  5.6
111 (29.3)
141 (37.2)
127 (33.5)

77.4  6.5
183.4  46.0
136.9  87.7
40.3  21.7
109.5  35.8
27.9  6.2
30 (32.6)
33 (35.9)
29 (31.5)

0.671
0.039
0.061
0.472
0.006c
0.639
0.534
0.755
0.358

Data are mean  standard deviation.
Men: e2 vs. e3/ e3, p ¼ 0.009; e2 vs. e4, p ¼ 0.006.
c
Men: e2 vs. e3/e3, p ¼ 0.002; e2 vs. e4, p ¼ 0.004; women: e2 vs. e3/e3, p ¼ 0.008; e2 vs. e4, p ¼ 0.009.
d
Data are N8 (%).
BMI, body mass index; APOE, apolipoprotein E; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol.
b
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Table 4. Baseline Characteristics of Men and Women by Vital Status
Men

a

2

BMI (kg/m )
Normal weightb
Overweightb
Obeseb
Alzheimer diseaseb
e2 carrierb
e3 carrierb
e4 carrierb
TCa (mg/dL)
LDL-Ca (mg/dL)
HDL-Ca (mg/dL)
TGa (mg/dL)

Survivors
(n ¼ 394)

Decedents
(n ¼ 94)

26.8  4.2
142 (36.0)
171 (43.4)
81 (20.6)
73 (18.5)
57 (14.5)
273 (70.6)
59 (15)
159.5  43.1
98.2  35.9
37.7  12.9
113.8  60.2

26.1  4.3
38 (40.4)
37 (39.4)
19 (20.2)
10 (10.6)
8 (8.5)
71 (75.5)
15 (16)
151.1  47.0
85.8  38.5
34.5  15.4
118.4  67.4

Women
Survivors
(n ¼ 457)

Decedents
(n ¼ 67)

28.5  5.7
128 (28.0)
169 (37.0)
160 (35.0)
88 (19.3)
49 (10.7)
325 (71.1)
83 (18.2%)
177.16  44.7
107.6  35.4
42.6  15.9
120.9  64.8

26.8  5.2
28 (41.8)
22 (32.8)
17 (25.4)
9 (13.4)
4 (6)
54 (80.6)
9 (13.4)
147.6  47.7
92.8  36.8
37.3  14.7
128.4  85.4

p
0.118

p for trend 0.001
0.219
0.127
0.337
0.811
0.095
0.003
0.004
0.540

P
0.018

p for trend 0.003
0.082
0.228
0.105
0.342
0.000
0.002
0.016
0.394

a

Data are mean  standard deviation.
Data are N8 (%).
BMI, Body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG,
triglycerides.
b

identification of five classes of patients at different risk of
mortality (Fig. 1A,B). The reference category was represented
by the subgroup with the lowest mortality. Thus, the ORs for
all the other subgroups were estimated with respect to the
reference class.
In females, the most important variable in discriminating
the risk of death was represented by the TC, with the lowest mortality in patients with values of TC greater than
180 mg/dL. On the opposite side of the regression tree, patients APOE e3 carriers, LDL-C values lower than 100 mg/dL
and with a normal weight represented the subgroup with the

Table 5. Risk Factor for 1-Year Mortality
According to Gender
OR (95% CI)

Normal weight
Overweight
Obese
e2 carrier
e3 carrier
e4 carrier
Hypercholesterolemia
High LDL-C
High TG
Lower HDL-C

Men

Women

1 (reference)
0.809 (0.488–1.339)
0.877 (0.474–1.621)
0.598 (0.270–1.104)
1 (reference)
1.024 (0.542–1.936)
0.819 (0.488–1.374)
0.860 (0.496–1.492)
1.197 (0.673–2.130)
1.640 (0.778–3.458)

1 (reference)
0.595 (0.325–1.088)a
0.486 (0.255–0.927)a
0.323 (0.094–1.119)b
1 (reference)
0.883 (0.404–1.931)b
0.350 (0.187–0.657)c
0.456 (0.235–0.882)c
1.316 (0.675–2.568)d
1.338 (0.768–2.330)e

a
Data were adjusted for age, diabetes, dyslipidemia, and cardiovascular disease.
b
Data were adjusted for total-cholesterol and LDL-C levels and
Alzheimer disease.
c
Data were adjusted for age, BMI, cardiovascular disease; APOE
genotype.
d
Data were adjusted for age, BMI, and diabetes.
e
Data were adjusted for age and cardiovascular disease.
OR, Odds ratio; CI, confidence interval; LDL-C, low-density
lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density
lipoprotein cholesterol; BMI, body mass index; APOE, apolipoprotein E.

highest mortality (OR ¼ 3.42, 95% CI ¼ 1.36–8.60). The class
of patients with TC lower than 180 mg/dL APOE e3 carrier
but with LDL-C greater than 100 mg/dL showed a significant risk of mortality (OR ¼ 2.59, 95% CI 1.09–6.18). For patients showing a TC lower than 180 mg/dL, APOE e3 carrier,
a LDL-C lower than 100 mg/dL but overweight or obese, the
estimated OR ¼ 3.17 (95% CI 1.42–7.08). Patients’ age
( p < 0.001) and presence of diabetes ( p ¼ 0.70), AD, and
cardiovascular diseases ( p ¼ 0.47) were included in the
model as global adjustment variables.
In males, the class of patients with lowest mortality were
those with LDL-C higher than 100 mg/dL and overweight or
obese. On the opposite side of the regression tree, patients
with LDL-C lower than 100 mg/dL, HDL lower than 40 mg/
dL, and APOE e3 carrier showed the highest mortality
(OR ¼ 1.97, 95% CI 1.04–3.74). Patients’ age ( p ¼ 0.057),
presence of diabetes ( p ¼ 0.175), AD, and cardiovascular
disease ( p ¼ 0.062) were included in the model as global
adjustment variables.
Discussion
The detection of gene–environment interactions can provide key information on the biological mechanisms of diseases and can lead to new insights into the prevention,
diagnosis, and treatment of chronic diseases in specific subgroups of the population. In this study, we evaluated the
relationship among APOE polymorphism, BMI, and dyslipidemia and how these factors modify overall mortality risk.
In agreement with previous studies,19,20 we found that the
mean concentrations of TC and LDL-C were APOE genotype
and BMI dependent in both male and female elderly patients.
In this study, TC and LDL-C levels were significantly higher
in obese than in normal weight patients, and in subjects
carrying e4 compared to subjects carrying e2 and e3 in both
males and females patients. In contrast, we did not find a
significant association between APOE alleles and serum
HDL-C concentrations in both men and women. A significant association between APOE polymorphism and HDL-C
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FIG. 1. Identification of subgroups at different risks for mortality: Results of RECPAM analysis. REPCAM analysis identified patient subgroups at different risks for mortality. The tree-growing algorithm modeled odds ratios (OR) after a logistic
regression with age, diabetes, and ischemic cardiomyopathy as global variables. Splitting variables are shown between
branches, whereas a condition sending patients to left or right sibling is on a relative branch. Class 1 with lowest mortality
was the reference category (OR ¼ 1). Circles indicate subgroups of patients; squares indicate the patient subgroup REPCAM
class. Numbers inside circles and squares represent the number of events (top) and the number of nonevents (bottom),
respectively. (A) Females. Global adjustment variables: Age OR ¼ 1.11 (1.06–1.16, diabetes OR ¼ 1.15 (0.57–2.34, ischemic
cardiomyopathy OR ¼ 0.71 (0.28–1.81. (B) Males. Global adjustment variables: Age OR ¼ 1.03 (1.00–1.07), diabetes OR ¼ 1.59
(0.81–3.08), ischemic cardiomyopathy OR ¼ 0.52 (0.26–1.03).

has been reported in some studies21 but not in others.22
Discrepancies among different studies may be due to other
factors that regulate the gene–environment interaction affecting HDL-C levels, such as physical activity, alcohol
consumption, and smoking.
In this population, no significant association between
APOE polymorphism and obesity was found. Only a few
studies have examined the relationship between APOE
polymorphisms and obesity. Although a significant association between APOE e4 allele status and obesity was reported
in children and young adults,23 other studies failed to find a

significant difference in the APOE allele and genotype frequencies between obese and nonobese subjects.24 In addition, none of these studies included hospitalized elderly
patients. A possible explanation for the lack of association
between BMI and APOE polymorphism in our population is
that BMI may be a poor indicator of obesity in elderly persons because body composition varies with age.
In addition, we found that, unlike in nonelderly patients,
higher levels of TC in females and LDL-C in males are associated with a lower risk of mortality. This paradoxical result is in line with previous reports showing that

EFFECT OF OBESITY AND APOE ON MORTALITY
hypercholesterolemia is associated with lower mortality in
elderly patients.25–27 There are several potential explanations
for these findings. It is possible that subjects with higher
cholesterol levels died before recruitment and that the sample represents a group of healthy survivors with traits that
make them less susceptible to disease caused by high cholesterol levels. Moreover, it is well known that cholesterol
levels decrease with age, and it has been suggested that low
cholesterol levels in the elderly represent a surrogate marker
of frailty or subclinical disease.28
In the present study, multivariate regression analysis shows
a negative relationship between BMI and mortality; and the
interaction analysis revealed that overweight and obesity are
protective in both males and females, even if with a different
grade of interaction, as suggested by the different composition
of the RECPAM tree-based algorithm, adjusted for age, diabetes, and AD or cardiovascular disease. These findings are in
agreement with previous studies.29–31 Several hypotheses
have been made to explain this effect of BMI on mortality in
the elderly: (1) The relationship among BMI, body fat, and fat
distribution weaken with aging; (2) lean mass and fat mass act
as important nutritional reserve during prolonged illness and
may be particularly important in old age as the incidence and
significance of illness and disease increase; (3) individuals
susceptible to the ill effects of elevated BMI may have already
died, determining a selective survival.
This study has limitations. First, our study evaluated the
interaction among APOE polymorphisms, BMI, dyslipidemia, and mortality risk, but did not evaluate the serum
concentrations of APOE, which has been shown to influence
the levels of circulating lipids.32 Second, in our study, we
used BMI as marker of obesity, instead of waist circumference or trunk fat mass measured by dual-energy X-ray absorptiometry (DEXA), which are better predictors of
mortality in old age.33 Finally, the use of hospitalized elderly
patients does not allow us to exclude that demographic selection could play a role in the reported differences. In conclusion, in elderly hospitalized patients, obesity and APOE
genotype influence the lipid profile and mortality risk. A
significant interaction among BMI, dyslipidemia, and APOE
genotype was observed that could identify elderly patients
with different risks of mortality.
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Marniemi J, Viikari J, Lehtimäki T. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein
changes: a 21-year follow-up study from childhood to
adulthood. The Cardiovascular Risk in Young Finns Study.
Clin Chem Lab Med 2007;45:592–598.
4. Ward H, Mitrou PN, Bowman R, Luben R, Wareham NJ,
Khaw KT, Bingham S. APOE genotype, lipids, and coronary
heart disease risk: A prospective population study. Arch
Intern Med 2009;169:1424–1429.
5. Zannis VI. Genetic polymorphism in human apolipoprotein
E. Methods Enzymol 1986;95:2358–2367.
6. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A,
Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U,
Danesh J. Association of apoliprotein E genotype with lipid
levels and coronary risk. JAMA 2007; 298:1300–1311.
7. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE e4 a ‘thrifty’ allele?. Ann
Hum Genet 1999;63:301–310.
8. Sudlow C, Martinez Gonzalez NA, Kim J, Clark C. Does
apolipoprotein E genotype influence the risk of ischemic
stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analysis of 31 studies
among 5961 cases and 17965 controls. Stroke 2006;37:364–
370.
9. Orsitto G, Seripa D, Panza F, Franceschi M, Cascavilla L,
Placentino G, Matera MG, Paris F, Capurso C, Solfrizzi V,
Dallapiccola B, Pilotto A. Apolipoprotein E genotypes in
hospitalized elderly patients with vascular dementia. Dement Geriatr Cogn Dis 2007;23:327–333.
10. Seripa D, Panza F, Franceschi M, D’Onofrio G, Solfrizzi V,
Dallapiccola B, Pilotto A. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer’s disease. Ageing Res Rev 2009;8:214–236.
11. Fillenbaum GG, Burchett BM, Lee JH, Blazer DG. Mortality
and apolipoprotein E in African-American, and White elders: An attempted replication. Am J Med Genet 2003;119A:
141–146.
12. Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton
MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA,
Breitner JC; Cache County Investigators. Apolipoprotein E
genotype and mortality: findings from the Cache County
Study. J Am Geriatr Soc 2005;53:935–942.
13. Slooter AJ, Cruts M, Van Broeckhoven C, Hofman A, van
Duijn CM. Apolipoprotein E and longevity: The Rotterdam
Study. J Am Geriatr Soc 2001;49:1258–1259.
14. Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay
AM, Kluft C, Knook DL, Westendorp RG. Association of
APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old
age. Am J Med Genet 2002;107:201–208.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnoses of Alzheimer’s disease: Report of NINCDS-ADRDA work group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer’s Disease. Neurology 1984;34:939–944.
16. Clinical Guidelines on the Identification, Evaluation and
Treatment of Overweight and Obesity in Adults. Bethesda,
MD: National Heart, Lung and Blood Institute; 1998.
17. Seripa D, Signori E, Gravina C, Matera MG, Rinaldi M, Fazio
VM. Simple and effective determination of apolipoprotein E

118

18.

19.

20.

21.

22.

23.

24.

25.

26.

ADDANTE ET AL.
genotypes by positive/negative polymerase chain reaction
products. Diagn Mol Pathol 2006;15:180–185.
Ciampi A, Negassa A, Lou Z. Tree-structured prediction for
censored survival data and the Cox model. J Clin Epidemiol
1995;48:675–689.
Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Hanaire-Broutin H, Perret B, Ferrières J. Obesity and alcohol
modulate the effect of apolipoprotein E polymorphism on
lipids and insulin. Obes Res 2003;11:1200–1206.
Srinivasan SR, Ehnholm C, Elkasabany A, Berenson GS.
Apolipoprotein E polymorphism modulates the association
between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. Metabolism 2001;50:696–
702.
Ikewaki K, Rader DJ, Zech LA, Brewer Jr HB. In vivo
metabolism of apolipoproteins A-I and E in patients with
abetalipoproteinemia: Implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res 1994;
35:1809–1819.
Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ,
Maguire G, Quinet E, Tall AR, Marcel YL, McPherson R.
Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: Relationship to apolipoprotein E genotype. J Lipid Res 1993;34:
437–446.
Srivastava N, Achyut BR, Prakash J, Agarwal CG, Pant DC,
Mittal B. Association of cholesteryl ester transfer protein
(TaqIB) and apolipoprotein E (HhaI) gene variants with
obesity. Mol Cell Biochem 2008;314:171–177.
Eto M, Watanabe K, Ishii K. Apolipoprotein E polymorphism and yperlipoproteinemia in obesity. Int J Obes 1989;
13:433–440.
Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, Pessina
AC, Staessen JA. Low-density lipoprotein cholesterol and
mortality in older people. J Am Geriatr Soc 2005;53:2159–2164.
Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux
R. Relationship between plasma lipids and all cause mortality in non demented elderly. J Am Geriatr Soc 2005;53:
219–226.

27. Chyou P, Eaker ED. Serum cholesterol concentrations and all
cause mortality in older people. Age Ageing 2000;29:69–74.
28. Schalk BW, Visser M, Deeg DJ, Bouter LM. Lower lvels of
serum albumin and total cholesterol and future decline in
functional performance in older persons: The Longitudinal
Aging Study Amsterdam. Age Ageing 2004;33:266–272.
29. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T,
Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort
of persons 50 to 71 years old. N Engl J Med 2006;355:763–778.
30. Janssen I, Mark AE. Elevated body mass index and mortality
risk in the elderly. Obes Rev 2007;8:41–59.
31. Janssen I. morbidity and mortality risk associated with an
overweight BMI in older men and women. Obesity
2007;15:1827–1840.
32. Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, Sans S, Do Carmo Martins M, De Backer
G, Siest G, Visvikis S. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels:
Results from APO Europe. Eur J Hum Gen 2002;10:841–850.
33. Price GM, Uauy R, Breeze E, Bulpitt CJ, Fletcher AE. Weight,
shape, and mortality risk in older persons: elevated waisthip ratio, not high body mass index, is associated with a
greater risk of death. Am J Clin Nutr 2006;84:449–460.

Address correspondence to:
Alberto Pilotto
Geriatric Unit & Gerontology-Geriatrics Research Laboratory
Department of Medical Sciences
IRCCS Casa Sollievo della Sofferenza
Viale Cappuccini 1
San Giovanni Rotondo (FG)
Italy
E-mail: alberto.pilotto@operapadrepio.it
Received: April 13, 2010
Accepted: May 14, 2010

